This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Anaesthetics, Pain Relief and ITU



April 2020

Liposomal bupivacaine for post-operative pain

Liposomal bupivacaine is in late-stage clinical development for the treatment of postoperative pain in adults. Post-operative pain is a common occurrence for those patients who have surgery. Controlling post-operative pain is important for ensuring a good patient experience, optimising post-operative outcomes and enhancing recovering, and the prevention of chronic postsurgical pain in the longer term.


March 2020

Remimazolam for general anaesthesia – first line

Remimazolam is an intravenous anaesthetic which is similar to the commonly used sleep-inducing drug midazolam, but it incorporates properties to make the offset of sedation faster and more predictable. If licensed, remimazolam will offer an additional first-line intravenous general anaesthetic treatment for induction and maintenance of general anaesthesia in adults.


October 2019

Bupivacaine and meloxicam (HTX-011) for post-operative pain

Bupivacaine and meloxicam (HTX-011) in a fixed-dose combination is in development for the management of post-operative pain. Post-operative pain is a typical example of acute pain. Acute pain typically lasts for less than 3-6 months (unlike chronic pain which carries on for longer than 12 weeks), and is provoked by identifiable stimuli and disappears as soon as the tissue injury or damage that had caused it is healed. All surgical procedures are associated with a certain level of post-operative pain. Opioids are often used to manage post-operative pain but carry the risk of harmful side effects, abuse and addiction.


March 2019

Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain

Tanezumab is in clinical development for the treatment of moderate to severe chronic pain associated with osteoarthritis and chronic low back pain. Pain is an unpleasant sensory experience associated with damage to body tissues due to an injury, physical pressure, or inflammation of some part of the body. Chronic pain is persistent or recurrent and lasts for longer than 12 weeks. Moderate pain interferes significantly with daily living activities, and severe pain is disabling and causes an inability to perform daily living activities. Effective long-term treatment options for managing moderate to severe chronic pain are limited. Currently available pain medicines like opioids and analgesics may increase the risks of addiction, gastrointestinal, cardiovascular and renal problems.


August 2018

Rimegepant for the treatment of Acute Migraine

Rimegepant potentially offers an alternative to current agents, particularly for patients who have contraindications to the use of triptans. This includes patients with underlying cardiovascular diseases, or who either do not respond or have inadequate or inconsistent response to triptans or are intolerant to them.


November 2017

Neridronic Acid (Nerixia) for Complex Regional Pain Syndrome

Currently there are no approved treatments for CRPS. Neridronic acid administered by injection is currently being developed to treat CRPS and early results indicate that it has the possibility to control the condition. If approved neridronic acid will be a potential new treatment for CRPS.


February 2017

Mirogabalin for pain due to fibromyalgia

Mirogabalin is a new drug to treat pain associated with fibromyalgia. Fibromyalgia is a long-term condition that causes pain all over the body. Mirogabalin is taken by mouth once a day at bedtime. If licensed, mirogabalin may offer patients with fibromyalgia an additional treatment option.


September 2016

XG 102 for post-operative inflammation and pain following cataract surgery

XG 102 is a new drug injected into the eye to treat pain and inflammation in people who have had a cataract operation. A cataract occurs when the lens in the eye becomes cloudy causing blurred vision. Cataracts are very common and usually affect those over the age of 65 years. More than 300,000 cataract …


August 2016

Tetrodotoxin for moderate to severe, inadequately controlled cancer-related pain

Cancer-related pain can arise from both ongoing tissue damage and treatments such as surgery or radiotherapy. Many patients use opioid-based pain killers to manage cancer-related pain but often they do not have complete pain relief. Tetrodotoxin is a new drug that blocks pain transmission. It is reported to be a well-tolerated, more potent analgesic than …


May 2016

AXS 02 (zoledronic acid) for type I complex regional pain syndrome

Complex regional pain syndrome is a painful condition that can occur in an arm or leg after a broken bone, operation or other injury. The cause of this condition is not understood, and there is currently no cure for complex regional pain syndrome. AXS 02 is a new drug for complex regional pain syndrome in …

Get Alerts